TABLE 2.
Baseline characteristics of patients.
| Group | Value |
| Age (years)-mean ± SD | 47.74 ± 13.85 |
| Female-n (%) | 20 (29.4) |
| BSA (m2)-mean ± SD | 1.80 ± 0.19 |
| SCDI (%)-median (IQR) | 4.28 (3.67) |
| Complicating disease-n (%) | |
| Hypertension | 18 (26.5) |
| Coronary heart disease | 4 (5.9) |
| Type 2 diabetes mellitus | 4 (5.9) |
| Gene mutation site-n (%) | |
| MYH7 | 16 (23.5) |
| MYBPC3 | 12 (17.6) |
| TNNI3 | 1 (1.5) |
| PTPN11 | 1 (1.5) |
| MYBPC3 and MYH7* | 1 (1.5) |
| Unknown sites | 37 (54.4) |
| NYHA functional class ≥ III-n (%) | 18 (26.5) |
| 6-min walk test distance (m)-mean ± SD | 451.5 ± 86.0 |
| Symptom-n (%) | |
| Chest pain | 66 (97.1) |
| Shortness of breath | 54 (79.4) |
| Syncope/pre-syncope | 31 (45.6) |
| LVEF (%)-median (IQR) | 58 (4) |
| IVS (mm)-mean ± SD | 23.56 ± 4.55 |
| Mitral valve SAM†-n (%) | |
| Grade 0 | 5 (7.4) |
| Grade 1 | 2 (2.9) |
| Grade 2 | 30 (44.1) |
| Grade 3 | 31 (45.6) |
| Resting LVOTG (mmHg)-mean ± SD | 78 ± 39 |
| Provoked LVOTG (mmHg)-mean ± SD | 126 ± 44 |
*Double mutation; †Measured at rest. BSA, body surface area; IQR, interquartile range; IVS, interventricular septum; LVEF, left ventricular ejection fractions; LVOTG, left ventricular outflow tract gradient; NYHA, New York heart association functional class; SAM, systolic anterior motion; SCDI, sudden cardiac death index.